Skip to main content
SpringerLink
Log in

Adalimumab/ustekinumab

Lack of efficacy, neurologic symptoms and hypesthesia

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Ottevanger R, et al. Addendum to "Remittance of primary cutaneous CD30+ lymphoproliferative disorder in a patient on adalimumab". JAAD Case Reports 45: 34, Mar 2024. Available from: URL: https://dx.doi.org/10.1016/j.jdcr.2023.12.018

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adalimumab/ustekinumab. Reactions Weekly 2002, 24 (2024). https://doi.org/10.1007/s40278-024-55401-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-024-55401-3

Search

Navigation